Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Febuxostat - Teijin Pharma

Drug Profile

Febuxostat - Teijin Pharma

Alternative Names: Adenuric; Feburic; Febuxostat XR; TEI-6720; TMX 67XR; TMX-67; TMX-67HK; TURAZIVE; Uloric

Latest Information Update: 09 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Teijin Pharma
  • Developer Astellas Pharma; Ipsen; Menarini; SK Chemicals; Takeda Pharmaceuticals USA; Te Arai BioFarma; Teijin Pharma
  • Class Antigouts; Antihypertensives; Carboxylic acids; Nitriles; Phenyl ethers; Small molecules; Thiazoles
  • Mechanism of Action Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gout; Hyperuricaemia
  • Registered Tumour lysis syndrome
  • Suspended Angina pectoris

Most Recent Events

  • 09 Aug 2019 Phase-II clinical trials in Gout (In children) in Japan before August 2019 (PO) (Teijin Pharma pipeline August 2019)
  • 09 Aug 2019 Phase-II clinical trials in Hyperuricaemia (In children) in Japan before August 2019 (PO) (Teijin Pharma pipeline August 2019)
  • 21 Feb 2019 The US FDA issued a black box warning for febuxostat for increased risk of death
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top